Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Liabilities and Shareholders Equity (2017 - 2025)

Historic Liabilities and Shareholders Equity for Cue Biopharma (CUE) over the last 9 years, with Q3 2025 value amounting to $31.6 million.

  • Cue Biopharma's Liabilities and Shareholders Equity fell 2938.18% to $31.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $126.8 million, marking a year-over-year decrease of 3742.18%. This contributed to the annual value of $32.2 million for FY2024, which is 4768.24% down from last year.
  • Latest data reveals that Cue Biopharma reported Liabilities and Shareholders Equity of $31.6 million as of Q3 2025, which was down 2938.18% from $40.7 million recorded in Q2 2025.
  • Cue Biopharma's 5-year Liabilities and Shareholders Equity high stood at $91.3 million for Q4 2022, and its period low was $22.3 million during Q1 2025.
  • For the 5-year period, Cue Biopharma's Liabilities and Shareholders Equity averaged around $65.1 million, with its median value being $73.2 million (2023).
  • Per our database at Business Quant, Cue Biopharma's Liabilities and Shareholders Equity surged by 4628.6% in 2021 and then tumbled by 5875.15% in 2025.
  • Over the past 5 years, Cue Biopharma's Liabilities and Shareholders Equity (Quarter) stood at $83.4 million in 2021, then grew by 9.45% to $91.3 million in 2022, then plummeted by 32.59% to $61.5 million in 2023, then crashed by 47.68% to $32.2 million in 2024, then fell by 1.7% to $31.6 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $31.6 million for Q3 2025, versus $40.7 million for Q2 2025 and $22.3 million for Q1 2025.